Active	Status	Sponsor type	Region	Phase	Filter
11 Active 36 Inactive 47 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

11 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hsu, Jason
NCT05660447: A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR	Recruiting	2/3	80	US	Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Rhopressa, Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud, Geri-Care Artificial Tears	Wills Eye	Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy	12/23	12/23
NCT05030220: Testosterone Levels and Cutibacterium	Recruiting	N/A	300	US		University of Washington	Arthroplasty, Replacement, Shoulder	01/25	01/27
NCT06464770: Optimizing Infection Prophylaxis Prior to Shoulder Surgery	Not yet recruiting	N/A	40	US	Chlorhexidine Gluconate	University of Washington	Arthroplasty Shoulder, Periprosthetic Joint Infection	12/26	12/27
Ho, Allen
NCT06229665: Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)	Active, not recruiting	2/3	75	US	Valeda Light Delivery System	LumiThera, Inc., National Eye Institute (NEI)	Dry Age-related Macular Degeneration	05/25	06/25
NCT06445114: Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer	Not yet recruiting	2	50	US	Cisplatin, Chemoradiation	Zachary Zumsteg	Oropharyngeal Cancer, Carcinoma	07/31	07/31
PMCAS, NCT02609685: Active Surveillance of Papillary Thyroid Microcarcinoma	Recruiting	N/A	216	US	Active Surveillance	Cedars-Sinai Medical Center	Papillary Thyroid Microcarcinoma	12/30	12/30
Regillo, Carl
NCT05409235: Nesvategrast (OTT166) in Diabetic Retinopathy (DR)	Completed	2	225	US	OTT166, Vehicle control	OcuTerra Therapeutics, Inc., Parexel	Diabetic Retinopathy	12/23	12/23
Garg, Sunir
NCT06130384: Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.	Completed	4	97	Canada, US	Use of bromfenac 0.09% to reduce intravitreal injection pain, Use of artificial tears to reduce intravitreal injection pain	Wills Eye	Pain, Intravitreal Injection, Pain, Acute	08/23	11/23
Pitcher, John
NCT06116916: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema	Recruiting	2	150	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Diabetic Macular Edema (DME)	11/25	12/25
NCT06116890: Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration	Recruiting	2	180	Japan, US, RoW	KHK4951, Aflibercept Injection	Kyowa Kirin, Inc.	Neovascular Age-Related Macular Degeneration (nAMD)	11/25	12/25
Formoso, Michele
NCT06229665: Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)	Active, not recruiting	2/3	75	US	Valeda Light Delivery System	LumiThera, Inc., National Eye Institute (NEI)	Dry Age-related Macular Degeneration	05/25	06/25